Study Phase 2

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Trial Information

Generic NameEpoetin alfaProduct NamePROCRIT®Therapeutic AreaBlood and Lymph ConditionsEnrollment102% Female3%% White90%
Product ClassColony-Stimulating FactorsSponsor Protocol NumberCR006076 (I88-009)Data PartnerJohnson & JohnsonCondition StudiedAIDS, AnemiaMean/Median Age (Years)39

Supporting Documentation

  • Collected Datasets Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.